(16) In 2022, the FDA approved it for treating adult patients with unresectable or metastatic HER2-positive breast cancer who had received a prior anti-HER2-based regimen either in the metastatic or in the neoadjuvant or adjuvant setting and whose disease recurred during or within 6 months of completing treatment. The gene discussed is ERBB2; the disease is breast cancer.